Alzheimer's drug candidate AS-S603 begins first human safety tests

This early-phase study is testing the safety and how the body handles a new oral drug called AS-S603, which is being developed to treat Alzheimer's disease. The trial involves 88 healthy volunteers, including Korean and Caucasian adults and Korean elderly people. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood. This study does not involve people with Alzheimer's and is focused on gathering initial safety data.